Allogene Therapeutics (ALLO)Frazier Life Sciences Management, L.P. added to its stake +18.6M shares

22.4M

Shares reported · +18.6M vs prior quarter

1.0%

Disclosed portfolio weight

$46.7M

Reported value

Holdings as of

Jun 30, 2026

Filed

Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Aug 12, 2026Company filing · Form 8-K · ResultsReported its results

What came next

1. Aug 21, 2026InsiderOfficer sold ~$63K of ALLO shares in the open market
2. Aug 31, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On August 31, 2026, Geoffrey Parker, the Executive Vice President and Chief Financial Officer and principal financial officer of Allogene Therapeutics, Inc. (the “Company”), provided notice of his retirement from the Company in all capacities, effective November 6, 2026.”

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Allogene Therapeutics

For Allogene Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ALLO page.

How this filing works

• SEC Form 13F

Other disclosures at Allogene Therapeutics

• SEC Form 4Aug 25, 2026
• SEC Form 4Apr 23, 2026
• SEC Form 4Apr 2, 2026
• SEC Form 4Mar 18, 2026
• SEC Form 4Mar 18, 2026
• SEC Form 4Mar 4, 2026

Everything OQRO holds on this company is on its ALLO page.